文献速递特殊人群用药治疗药物监测与药物基因组学

妊娠及产后S-西酞普兰血浆浓度变化

Changes in S-Citalopram Plasma Concentrations Across Pregnancy and Postpartum.
PubMed 文献 · Clin Pharmacol Ther · 2025-03-18

本研究前瞻性观察30名单胎妊娠并继续服用西酞普兰/艾司西酞普兰的抑郁症患者,每月测血药浓度。妊娠期S-西酞普兰浓度剂量比无显著变化,但产后6-8周平均升高63%,CYP2C19中间代谢者在妊娠36周时浓度剂量比较产后降低35.7%,可能面临治疗浓度不足风险。

要点

  • 妊娠期S-西酞普兰浓度剂量比稳定,无需常规调整剂量。
  • 产后6-8周浓度剂量比平均升高63%,需关注母体浓度变化。
  • CYP2C19中间或慢代谢者妊娠期浓度可能不足,需个体化评估。

核心结论

  • 妊娠期S-西酞普兰浓度剂量比无显著变化,但产后早期显著升高。
  • CYP2C19中间代谢者妊娠36周浓度剂量比较产后降低35.7%,可能治疗浓度不足。

研究设计与样本

  • 前瞻性观察性队列研究,纳入30名单胎妊娠并继续服用西酞普兰/艾司西酞普兰的抑郁症患者。
  • 妊娠期每月及产后两次于给药后24小时采血,测定西酞普兰、去甲西酞普兰和二去甲西酞普兰对映体浓度。

主要发现

  • 与36周参考值相比,妊娠期S-西酞普兰浓度剂量比无显著差异。
  • 产后6-8周平均浓度剂量比升高63%(P < 0.001)。
  • 产后晚期平均浓度剂量比为1.20 ± 0.64,36周为0.92 ± 0.46(P = 0.06)。
  • CYP2C19中间代谢者产后晚期浓度剂量比约为快代谢/超快代谢者的2倍。
  • 妊娠36周时CYP2C19中间代谢者浓度剂量比较产后降低35.7%,快代谢和快/超快代谢者分别降低15.4%和18.5%。

临床怎么用

  • 妊娠期可维持西酞普兰/艾司西酞普兰剂量,但CYP2C19中间或慢代谢者需警惕浓度不足。
  • 产后6-8周应关注浓度升高相关不良反应,必要时监测血药浓度。

局限性

  • 样本量较小(30例),可能影响统计效能。
  • 未报告剂量调整对临床结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder is a common disorder in pregnancy. Although citalopram/escitalopram is the second most frequently prescribed antidepressant for pregnant people, information about its pharmacokinetics in pregnancy is limited. We investigated plasma (S)-citalopram concentration to dose (C/D) ratios across pregnancy and postpartum and the effect of pharmacogenetics on its elimination. This prospective observational cohort study enrolled 30 participants with a singleton pregnancy who chose to continue citalopram/escitalopram during pregnancy for a prior diagnosis of major depression. Monthly blood samples were obtained 24 hours post-dose across pregnancy and twice postpartum for measurement of plasma citalopram, desmethylcitalopram, and didesmethylcitalopram enantiomer concentrations. Compared with the 36-week reference, (S)-citalopram C/D ratios were not significantly different throughout pregnancy. However, the mean (S)-citalopram C/D ratio was elevated by 63% (P < 0.001) 6 to 8 weeks after delivery before it decreased to a mean C/D ratio in the later post-birth period that was marginally different than at 36 weeks (1.20 ± 0.64 vs. 0.92 ± 0.46, respectively; P = 0.06). Analyzing the results by cytochrome P 450 (CYP) 2C19 phenotype, the mean late postpartum (S)-citalopram concentration to dose ratio in intermediate metabolizers was approximately twice that in extensive, rapid, or ultrarapid metabolizers. However, at the 36-week reference point, the mean concentration to dose ratio in pregnant CYP2C19 intermediate metabolizers was 35.7% lower than the distant postpartum ratio, while the ratios in extensive and rapid/ultrarapid metabolizers were 15.4% and 18.5% lower, respectively. Without dose adjustment, people with intermediate or poor CYP2C19 activity may be at risk for subtherapeutic S-citalopram concentrations during pregnancy.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Stika CS, Avram MJ, George AL, et al. Changes in S-Citalopram Plasma Concentrations Across Pregnancy and Postpartum. Clin Pharmacol Ther. 2025. PMID: 40099712. doi:10.1002/cpt.3642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。